Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
TRDA Stock Chart & Stats
$13.50
-$0.56(-3.25%)
At close: 4:00 PM EST
$13.50
-$0.56(-3.25%)
Day’s Range― - ―
52-Week Range$4.93 - $14.36
Previous CloseN/A
Volume35.15K
Average Volume (3M)211.50K
Market Cap
$516.84M
Enterprise Value$477.38M
Total Cash (Recent Filing)$295.70M
Total Debt (Recent Filing)$50.93M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
May 07, 2026EPS Estimate
-1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding38,284,313
10 Day Avg. Volume181,263
30 Day Avg. Volume211,497
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.39
Price to Sales (P/S)16.73
P/FCF Ratio-3.28
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue18.78
Enterprise Value/Gross Profit-34.53
Enterprise Value/Ebitda-3.17
Forecast
1Y Price Target
$20.50Price Target Upside51.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.91
Revenue Forecast (FY)$24.92M
Bulls Say, Bears Say
Bulls Say
Clinical ReadoutsEarly Cohort 1 results from the Elevate 44 Phase I/II trial could serve as a major clinical inflection point if they show meaningful increases in dystrophin with an acceptable safety profile.
Delivery TechnologyThe endosomal escape vehicle delivery platform may enable better muscle cell uptake and endosomal escape than unconjugated or TfR1-based approaches, potentially yielding stronger dystrophin expression across tissues.
Pipeline Breadth And Regulatory ProgressRegulatory authorization in the U.K. for an exon 50 study and multiple advancing programs across regions expand the number of potential value-inflecting clinical readouts and support upside relative to peers with low enterprise value.
Bears Say
Binary Clinical Dependency And Valuation RiskCompany value appears heavily dependent on early-stage clinical readouts, so negative or inconclusive results could materially reduce investor expectations and share valuation.
Regulatory Dosing UncertaintyOngoing discussions with regulators about increasing planned doses introduce uncertainty around optimal dosing and could complicate development timelines and approval pathways.
Safety RiskReports of low magnesium and kidney-related safety signals in similar exon-skipping programs underscore the risk that the company’s candidates could encounter comparable clinically meaningful adverse effects.
Entrada Therapeutics Inc News
TRDA FAQ
What was Entrada Therapeutics Inc’s price range in the past 12 months?
Entrada Therapeutics Inc lowest stock price was $4.93 and its highest was $14.36 in the past 12 months.
What is Entrada Therapeutics Inc’s market cap?
Entrada Therapeutics Inc’s market cap is $516.84M.
When is Entrada Therapeutics Inc’s upcoming earnings report date?
Entrada Therapeutics Inc’s upcoming earnings report date is May 07, 2026 which is in 24 days.
How were Entrada Therapeutics Inc’s earnings last quarter?
Entrada Therapeutics Inc released its earnings results on Feb 26, 2026. The company reported -$0.94 earnings per share for the quarter, beating the consensus estimate of -$1.15 by $0.21.
Is Entrada Therapeutics Inc overvalued?
According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued.
Does Entrada Therapeutics Inc pay dividends?
Entrada Therapeutics Inc does not currently pay dividends.
What is Entrada Therapeutics Inc’s EPS estimate?
Entrada Therapeutics Inc’s EPS estimate is -1.04.
How many shares outstanding does Entrada Therapeutics Inc have?
Entrada Therapeutics Inc has 38,284,313 shares outstanding.
What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?
Entrada Therapeutics Inc reported an EPS of -$0.94 in its last earnings report, beating expectations of -$1.15. Following the earnings report the stock price went up 6.761%.
Which hedge fund is a major shareholder of Entrada Therapeutics Inc?
Currently, no hedge funds are holding shares in TRDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Entrada Therapeutics Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.50 (51.85% Upside)
$20.50 (51.85% Upside)
Blogger Sentiment
Bullish
TRDA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 250.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days >0.1%
Last 30 Days >0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
71.97%
12-Months-Change
Fundamentals
Return on Equity
-39.83%
Trailing 12-Months
Asset Growth
-28.30%
Trailing 12-Months
Company Description
Entrada Therapeutics Inc
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
TRDA Stock 12 Month Forecast
Average Price Target
$20.50
▲(51.85% Upside)
Technical Analysis
―
Black Diamond Therapeutics
―
C4 Therapeutics
―
―
Sagimet Biosciences, Inc. Class A
―
Ownership Overview
36.56% Insiders
8.49% Mutual Funds
35.13% Other Institutional Investors
11.58% Public Companies and
Individual Investors